The global Antisense & RNAi Therapeutics Market size is expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%, according to a new report by Grand View Research, Inc. Development in biological vectors and nanotechnology and rising external funding to conduct clinical studies pertaining to introduction of novel drug moieties play a vital role in the process of product development and fuel growth in this market.
Multinational
healthcare establishments promote awareness and aid in finding novel therapies
for treatment of different disorders. Private institutes such as California
Institute of Regenerative Medicine and ALS Association that are involved in
conducting trials by funding the research institutes and pharmaceutical
organizations are expected to fuel sector growth significantly. Moreover,
government initiatives for speeding the development of drug delivery platforms
in order to reduce the disease burden are attributive for industrial growth.
Antisense
& RNAi therapeutics services are applicable in treatment of several range
of diseases that target the nucleic acid and affect cell growth cycle. miRNA is
attracting considerable interest in its ability to restore gene expression and
correct protein production thereby influencing industrial progress. Developments
that involve research for utilization of different routes to deliver the
desired effect of candidate moiety before its removal from blood are
anticipated to fuel sector growth.
However,
challenges associated with the drug delivery are expected to impede growth to
certain extent. Delivery technologies that enable mitigation of the off-target
effects and undesirable immunological stimulation need to be introduced to
reduce the effect of restraining factors.
Related Press Release@ Antisense
& RNAi Therapeutics Market Report
Antisense & RNAi Therapeutics Market Report
Highlights
- Antisense
RNA was the largest technology segment in 2018 owing to the advantages
offered by this technology over the antisense technology
- Based on the
triggering of the RNA molecules this technology is segmented into siRNA
and miRNA
- Owing to
significant involvement of miRNA in maintaining cell’s identity these are
used to provide a deep insight into cancer metastasis
- Usage of
RNAi therapy to selectively target SNPs in genetic disorders is a major
factor expected to provide this segment with a number of potential
treatment avenues over the forecast period
- siRNA is
highly specific and allows induction at advanced stages of cancer growth
as compared to chemotherapy, which is attributive for the largest share of
oncology applications
- Extensive
R&D programs carried out in this sector to develop an efficient method
for the delivery of RNA silencing therapeutic products is anticipated to
propel growth
List of Key
Players in Antisense & RNAi Therapeutics Market
·
Ionis Pharmaceuticals
·
GSK
·
Alnylam Pharmaceuticals
·
Marina Biosciences
·
Sanofi-Genzyme
·
Quark Pharmaceuticals
·
Gene Signal
·
Benitec Biopharma
About Us:
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment